Yung Hong Wa, Xue Luzheng, Tolkovsky Aviva M
Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge, UK.
FEBS Lett. 2002 Nov 6;531(2):168-72. doi: 10.1016/s0014-5793(02)03497-x.
We have examined whether the apoptosis-specific protein p45ASP and human Apg5 are identical proteins. Like p45ASP, myc-hApg5 cross-reacted with a c-Jun antibody and approximately 50% of myc-hApg5 was bound to a Triton X-100-insoluble fraction in HeLa cells. However, soluble myc-hApg5 was degraded during apoptosis induced by staurosporine or TNFalpha/cycloheximide whilst expression of soluble p45ASP was stabilised. Furthermore, myc-hApg5 degradation was blocked by the caspase inhibitor Boc-Asp(OMe)FMK whilst p45ASP expression was eliminated. Moreover, myc-hApg5 ( approximately 32 kDa) never assumed the size of p45ASP (45 kDa). It is therefore likely that p45ASP and human Apg5 are distinct proteins although they do share some common characteristics.
我们已经研究了凋亡特异性蛋白p45ASP与人类Apg5是否为同一蛋白。与p45ASP一样,myc-hApg5能与c-Jun抗体发生交叉反应,并且在HeLa细胞中约50%的myc-hApg5与Triton X-100不溶性组分结合。然而,可溶性myc-hApg5在星形孢菌素或TNFα/环己酰亚胺诱导的凋亡过程中被降解,而可溶性p45ASP的表达则保持稳定。此外,半胱天冬酶抑制剂Boc-Asp(OMe)FMK可阻断myc-hApg5的降解,而p45ASP的表达则被消除。而且,myc-hApg5(约32 kDa)的大小从未与p45ASP(45 kDa)一致。因此,尽管p45ASP和人类Apg5确实有一些共同特征,但它们很可能是不同的蛋白。